Home / Market News / $ASND

$ASND news and market catalysts

The 21 most recent market catalysts affecting $ASND, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

21 catalysts 5 high impact 11 bullish 5 bearish Biotechnology
Sep 15, 2026 Corporate Catalyst Bearish Impact 75
Why Is Ascendis Pharma Stock Trading Lower on Tuesday?
Ascendis Pharma announced two key events: regaining full rights to its TransCon technology for metabolic and cardiovascular diseases from Novo Nordisk and a $400 million share repu…
Sep 15, 2026 Corporate Catalyst Bearish Impact 85
Ascendis Pharma shares are trading lower after the company announced it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. Also, Raymond James downgraded the stock from Strong Buy to Outperform.
The headline indicates a significant negative reaction to Ascendis Pharma's announcement. Regaining exclusive rights to TransCon technology in metabolic and cardiovascular diseases…
Sep 15, 2026 Corporate Catalyst Bearish Impact 55
Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287
Raymond James analyst Martin Auster downgraded Ascendis Pharma (ASND) from 'Strong Buy' to 'Outperform'. While the price target was maintained at $287, the downgrade signals a slig…
Sep 14, 2026 Corporate Catalyst Bullish Impact 65
Ascendis Pharma Authorizes Up To $400M Share Repurchase Program
Ascendis Pharma's Board of Directors has authorized a share repurchase program of up to $400 million. This action indicates that the company's management believes its shares are cu…
Sep 14, 2026 Corporate Catalyst Neutral Impact 85
Ascendis Pharma Regains Exclusive Rights To TransCon Tech Products After Ending Novo Nordisk Collaboration; Ascendis To Initiate Multiple Programs In Metabolic And Cardiovascular Diseases, Including Obesity
Ascendis Pharma (ASND) has announced the termination of its collaboration agreement with Novo Nordisk (NVO), resulting in ASND regaining full, exclusive rights to its TransCon tech…
Sep 10, 2026 Corporate Catalyst Bullish Impact 75
Ascendis Pharma Says Growth Drug Shows Benefits in Infants
Ascendis Pharma released promising 52-week data from its reACHin trial for TransCon CNP in infants with achondroplasia. The drug demonstrated stabilization or improvement in forame…
Sep 9, 2026 Corporate Catalyst Bullish Impact 75
Ascendis Announces Week 52 Data From Open-Label Sentinel Cohort Portion Of reACHin Trial Showing Treatment With Once-Weekly TransCon CNP Provided Stabilization Or Improvement In Foramen Magnum Stenosis And Linear Growth Benefits In Infants With Achondroplasia
Ascendis Pharma released promising Week 52 data for its drug TransCon CNP in treating achondroplasia in infants. The data indicates that the treatment stabilized or improved forame…
Sep 8, 2026 Corporate Catalyst Neutral Impact 65
Reported Earlier, Ascendis Pharma To Present New Infant Achondroplasia Trial Data At ESPE 2026
Ascendis Pharma announced an upcoming presentation of the first sentinel cohort data from its pivotal reACHin Trial of TransCon CNP in infants with achondroplasia at the ESPE 2026 …
Sep 2, 2026 Corporate Catalyst Bullish Impact 55
Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312
Oppenheimer analyst Leland Gershell has maintained an 'Outperform' rating on Ascendis Pharma (ASND) and slightly raised the price target from $304 to $312. This action signifies a …
Aug 31, 2026 Corporate Catalyst Bullish Impact 85
Ascendis Pharma shares are trading higher after BioMarin granted the company a non-exclusive, worldwide, royalty-bearing license, allowing it to continue researching, developing, manufacturing, and commercializing navepegritide-related products without restriction.
The non-exclusive, worldwide, royalty-bearing license from BioMarin to Ascendis Pharma for navepegritide-related products is a strong positive catalyst for Ascendis. It eliminates …
Aug 31, 2026 Corporate Catalyst Bearish Impact 75
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday
Ascendis Pharma's significant stock jump is directly attributable to the resolution of its global patent disputes with BioMarin Pharmaceutical concerning the drug Yuviwel. This set…
Aug 31, 2026 Corporate Catalyst Bullish Impact 75
Ascendis, Biomarin Enter Binding Global Settlement And License Agreement Resolving All Litigation, Granting Ascendis Worldwide Rights To Develop, Commercialize Navepegritide Products, With Royalty Payments On YUVIWEL Sales Through 2030
Ascendis Pharma A/S and BioMarin Pharmaceutical Inc. have entered into a binding global settlement and license agreement. This resolves all ongoing litigation between the two compa…
Aug 27, 2026 Corporate Catalyst Neutral Impact 65
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
The filing details new analyst coverage for Ascendis Pharma (ASND), DigitalOcean Holdings (DOCN), and Odyssey Therapeutics (ODTX), all receiving 'Buy' ratings and significant price…
Aug 27, 2026 Corporate Catalyst Neutral Impact 65
HC Wainwright & Co. Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $345
HC Wainwright & Co. analyst Mitchell S. Kapoor has initiated coverage on Ascendis Pharma (ASND) with a 'Buy' rating and a price target of $345. This is a positive development for A…
Aug 19, 2026 Corporate Catalyst Neutral Impact 65
BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319
BMO Capital analyst David Lebowitz initiated coverage on Ascendis Pharma (ASND) with an 'Outperform' rating and a $319 price target. This is a significant event for ASND as new ana…
Aug 14, 2026 Corporate Catalyst Bullish Impact 55
TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341
TD Cowen analyst Yaron Werber maintained a 'Buy' rating on Ascendis Pharma and raised the price target from $325 to $341. This action signals continued bullish sentiment from a pro…
Aug 14, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $290
RBC Capital's analyst Luca Issi has maintained an 'Outperform' rating on Ascendis Pharma and raised the price target from $280 to $290. This action signals continued bullish sentim…
Aug 14, 2026 Corporate Catalyst Bearish Impact 55
Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329
Barclays analyst Eliana Merle maintained an 'Overweight' rating on Ascendis Pharma, signaling continued confidence in the company's long-term prospects. However, the price target w…
Aug 13, 2026 Corporate Catalyst Bullish Impact 95
Ascendis Pharma Q2 Adj. EPS $1.05 Beats $0.78 Estimate, Sales $394.437M Beat $353.800M Estimate
Ascendis Pharma announced Q2 adjusted EPS of $1.05, significantly surpassing the $0.78 consensus estimate, and sales of $394.437 million, also beating the $353.800 million estimate…
Aug 6, 2026 Corporate Catalyst Bullish Impact 85
Ascendis Pharma Says Week 78 COACH Data Show TransCon CNP Plus TransCon hGH Combination Tripled Height Z-Score Efficacy vs. Monotherapy In Achondroplasia; Reports Over 170 YUVIWEL US Patient Enrollments
This is a major positive catalyst for Ascendis Pharma. The 'tripled height Z-score efficacy' is a strong clinical outcome, suggesting a highly effective treatment for achondroplasi…
Jul 23, 2026 Corporate Catalyst Bullish Impact 55
Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $275
Morgan Stanley analyst Maxwell Skor maintained an 'Overweight' rating on Ascendis Pharma and raised the price target from $256 to $275. This action signals continued confidence fro…
 Join the waitlist for full signal validation →

New to reading filings? What an SEC 8-K is and why it moves prices

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.